WO1995017189A1 - NOUVELLE UTILISATION D'ANTAGONISTES DES RECEPTEURS δ-OPIOÏDES - Google Patents

NOUVELLE UTILISATION D'ANTAGONISTES DES RECEPTEURS δ-OPIOÏDES Download PDF

Info

Publication number
WO1995017189A1
WO1995017189A1 PCT/SE1994/001210 SE9401210W WO9517189A1 WO 1995017189 A1 WO1995017189 A1 WO 1995017189A1 SE 9401210 W SE9401210 W SE 9401210W WO 9517189 A1 WO9517189 A1 WO 9517189A1
Authority
WO
WIPO (PCT)
Prior art keywords
opioid receptor
active ingredient
pharmaceutical preparation
naltrindole
receptor antagonist
Prior art date
Application number
PCT/SE1994/001210
Other languages
English (en)
Inventor
Carl-Johan Dalsgaard
Original Assignee
Astra Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag
Priority to AU13942/95A priority Critical patent/AU1394295A/en
Publication of WO1995017189A1 publication Critical patent/WO1995017189A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine

Definitions

  • the present invention is related to the novel use of ⁇ - opioid receptor antagonists or a pharmaceutically and pharmacologically acceptable salt thereof, in the manufacture of pharmaceutical preparations with antirheumatic effect.
  • proenkephalin which is the precursor for leu-enkephalin the endogenous ⁇ -opoid receptor ligand (Zurawaski et al, Science 232 (1986) 772-775; Martin et al, J. Neurosci. Res. (18 (1987) 82-87; Rosen et al, J. Immunol. 143 (1989) 3703-3707: Przewlocki et al, Neuroscience 48:2
  • RA Rheumatoid arthritis
  • Current medications aim at control of symptoms of inflammation or prevent progression of the disease and all drugs employed involve the risk of serious side-effects.
  • the present patent application describes ⁇ -receptor antagonists with therapeutic effects on the onset of RA.
  • the compounds according to this invention have a general characteristic, i.e. they show binding to the ⁇ -opioid receptor and act as competitive antagonists. They may comprise of small organic molecules as naltrindole and analogues of naltrindole or peptides, modified peptides and peptoides.
  • the invention also includes compounds that after administration to a living organism may be transformed therein to a compound that exerts ⁇ -opioid receptor antagonism. Furthermore, the invention includes compounds that regulate or modify the endogenous turnover of ⁇ - opioid receptor ligands, i.e. by blocking synthesis and/or release. Such compounds are a further aspect of this invention.
  • the compounds of this invention may be administered in form of free basis or their pharmaceutically and pharmacologically acceptable salts with non-toxic acids. Some typical implementations of these salts are the hydrobromide, hydrochloride phosphate, sulphate citrate or tartrate.
  • the way of administration can be orally, intramuscularly, subcutaneously, intravenously, rectally, transdermally, by inhalation or nasally, among others.
  • Peptides may be administered in different formulations to allow uptake and reduce break-down or guided transdermally by electrical stimulation (iontophoresis) .
  • ⁇ -opioid receptor antagonists at doses with no apparent systemic toxic or general cytotoxic effects block onset of arthritis in the collagen II induced arthritis in mouse.
  • Suitable doses of the ⁇ -opioid receptor antagonists are 1 ⁇ g-100 mg/kg, preferably 1-20 mg/kg.
  • a preferred way of administration is orally, but other ways of administration are also possible.
  • the collagen II induced arthritis model is based upon a previously described method (Jansson and Holmdahl, Clin. exp. immunol. 1992) 89, 446-451.
  • the (B10Q x DBA/1)F-L mice (QD) were bread and kept in the Animal Unit of the Biomedical Center, Uppsala, Sweden.
  • One group of 19 immunized mice received injections of 60 ⁇ g naltrindole in 100 ⁇ l PBS s.c. for 4 consecutive days (day 17-20 after immunazation) .
  • a control group of 19 immunized mice received the same treatment except for that they did not receive naltrindole.
  • the pharmaceutical preparation was prepared by dissoluting the active ingredient in PBS.

Landscapes

  • Health & Medical Sciences (AREA)
  • Emergency Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Utilisation d'antagonistes de récepteurs δ-opioïdes ou d'un de leurs sels acceptables pharmaceutiquement dans le but de préparer un produit pharmaceutique possédant un effet antirhumatismal.
PCT/SE1994/001210 1993-12-22 1994-12-16 NOUVELLE UTILISATION D'ANTAGONISTES DES RECEPTEURS δ-OPIOÏDES WO1995017189A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU13942/95A AU1394295A (en) 1993-12-22 1994-12-16 New use of delta-opioid receptor antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9304236-4 1993-12-22
SE9304236A SE9304236D0 (sv) 1993-12-22 1993-12-22 New use

Publications (1)

Publication Number Publication Date
WO1995017189A1 true WO1995017189A1 (fr) 1995-06-29

Family

ID=20392169

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1994/001210 WO1995017189A1 (fr) 1993-12-22 1994-12-16 NOUVELLE UTILISATION D'ANTAGONISTES DES RECEPTEURS δ-OPIOÏDES

Country Status (3)

Country Link
AU (1) AU1394295A (fr)
SE (1) SE9304236D0 (fr)
WO (1) WO1995017189A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150352100A1 (en) * 2013-01-21 2015-12-10 Avant Derma Pte. Ltd. Use of selective delta-opioid receptor antagonists and specific sensory receptor ligands

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0373744A2 (fr) * 1988-12-15 1990-06-20 Baker Norton Pharmaceuticals, Inc. Utilisation du nalméfène ou du naltrexone dans le traitement des maladies auto-immunes
EP0377272A2 (fr) * 1989-01-04 1990-07-11 Baker Norton Pharmaceuticals, Inc. Utilisation de nalméfène ou naltrexone pour l'obtention d'un médicament destiné au traitement de l'inflammation dans l'arthrite ou dans des maladies inflammatoires associées
EP0456833A1 (fr) * 1989-11-28 1991-11-21 Toray Industries, Inc. Immunosuppresseur et procede de preparation d'un tel medicament

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0373744A2 (fr) * 1988-12-15 1990-06-20 Baker Norton Pharmaceuticals, Inc. Utilisation du nalméfène ou du naltrexone dans le traitement des maladies auto-immunes
EP0377272A2 (fr) * 1989-01-04 1990-07-11 Baker Norton Pharmaceuticals, Inc. Utilisation de nalméfène ou naltrexone pour l'obtention d'un médicament destiné au traitement de l'inflammation dans l'arthrite ou dans des maladies inflammatoires associées
EP0456833A1 (fr) * 1989-11-28 1991-11-21 Toray Industries, Inc. Immunosuppresseur et procede de preparation d'un tel medicament

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ACTA MED. AUSTRIACA JG., Volume 15, No. 5, 1988, F. RAINER, "Immunosuppressive Therapy in Rheumatoid Arthritis", pages 137-140. *
CRITICAL CARE MEDICINE, Volume 18, No. 2, 1990, MICHAEL E. WEINBLATT et al., "Newer Immunosuppressive Therapies for Rheumatoid Arthritis", pages 126-131. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150352100A1 (en) * 2013-01-21 2015-12-10 Avant Derma Pte. Ltd. Use of selective delta-opioid receptor antagonists and specific sensory receptor ligands

Also Published As

Publication number Publication date
SE9304236D0 (sv) 1993-12-22
AU1394295A (en) 1995-07-10

Similar Documents

Publication Publication Date Title
US4994446A (en) Drug system
US20060100205A1 (en) Compositions for affecting weight loss
JP2002507962A (ja) トラマドールとｎｍｄａの組合せによる痛み軽減法
TW200406369A (en) Organic compounds
JP2000508341A (ja) 片頭痛の治療法及び薬効の強化組成物
US20130039905A1 (en) Diazoxide For Use In The Treatment Or Prevention Of A Central Nervous System (CNS) Autoimmune Demyelinating Disease
AU4399093A (en) Des-tyr dynorphin analogues
US5432176A (en) Method of retarding the progression of chronic renal failure
Dafny et al. Alteration of morphine withdrawal to naloxone by interferon
US5187177A (en) Method and a pharmaceutical preparation for treating pain
AU2002310788A1 (en) Treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists
EP1392348A1 (fr) Traitement de la demence et de maladies neurodegeneratives par des doses intermediaires d'antagonistes de luteoluberine
Saphier et al. α-Interferon inhibits adrenocortical secretion via μ1-opioid receptors in the rat
JPH10505087A (ja) 非麻薬性鎮痛剤および無痛エンハンサーを含有する疼痛緩和組成物
KR20050106038A (ko) 심장질환 및 신장질환의 치료를 위한 아데노신 ａ1 수용체길항제
WO2001012204A2 (fr) Compositions et procede de traitement de l'intoxication a l'acetaminophene
US10624945B2 (en) Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain
KR20050086465A (ko) 동통 해소 약물
EP0942749A2 (fr) Traitement des maladies epidermiques causees par le stress au moyen de corticotropine a production d'antagonistes hormonaux et inhibiteurs de degranularisation de basophiles/mastocytes epidermiques
EP0213676B1 (fr) Compositions pharmaceutiques contenant l'ACTH(1-24)pour la thérapie des états de choc et des insuffisances respiratoires et cardiocirculatoires
US6437093B1 (en) Methods of treatment comprising administration of Substance P
WO1995017189A1 (fr) NOUVELLE UTILISATION D'ANTAGONISTES DES RECEPTEURS δ-OPIOÏDES
EP0844241A1 (fr) Inhibiteur de la dependance / de la resistance a l'egard des analgesiques narcotiques
WO2014136118A1 (fr) Traitement du syndrome de stress post-traumatique avec un antagoniste des récepteurs de mélanocortines
EP0315681B1 (fr) Utilisation de nalmefère pour l'obtention d'un médicament destiné au traitement des lesions du système nerveux central

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: US

Ref document number: 1995 381869

Date of ref document: 19950207

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA